Bacteroides cellulosilyticus-directed glycans relieve colitis

Bacteroides cellulosilyticus correlates with inflammatory bowel disease (IBD). Targeting an increase in abundance of B. cellulosilyticus is a feasible approach to treating IBD. Although B. cellulosilyticus is responsive to dietary components, untargeted manipulation cannot focus on target microbe and can lead to an increase in harmful bacteria in the microbiota. Despite breakthroughs in methods for regulating specific microbes, the protocols are expensive, time-consuming, and difficult to follow. Glycans based on microbial-carbohydrate-active enzymes (CAZymes) that target a specific microbiota would provide a potential solution.